Talking therapy via video aims to boost self-care in lung disease patients
NCT ID NCT07179562
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether motivational interviewing, delivered through video calls and online platforms, can improve self-care in 124 adults with idiopathic pulmonary fibrosis (IPF). Participants will be randomly assigned to receive the counseling or usual care. Researchers will measure changes in self-care behaviors, anxiety, quality of life, and hospital visits. The goal is to see if remote support can help patients manage their condition better.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- motivational interviewing (a counseling approach delivered remotely via video calls and digital platforms)
- What this could lead to
- If it works, this could show that remote counseling helps people with IPF better manage their daily care and reduce hospital visits.
- What could go wrong
- This is a small, early-stage study focused on behavior change, not a drug or cure. The results may not apply to all IPF patients, and the benefit may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 124 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2025
An estimate. Start dates often move.
- Expected to finish
-
Oct 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosed with idiopathic pulmonary fibrosis according to the 2018 guidelines of the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association, * Diagnosed with IPF for at least 1 year, * Aged 18 years or older, * Able to express willingness and provide consent to participate in the study, * In possession of a tablet, smartphone, or computer and internet access via mobile or fixed network. Exclusion Criteria: * Diagnosed with dementia, * Unable to speak, read, or write in Italian, * Legally blind or deaf, * In advanced stage of disease (receiving oxygen therapy at 10 to 15 liters per minute).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Idiopathic pulmonary fibrosis (IPF) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sharper CT scans may solve a lung disease diagnostic puzzle
- Can a new daily pill slow lung scarring in IPF?
- Which finger or earlobe? a study tests the best spot for oxygen monitoring in lung disease
- Can a new drug slow lung scarring in IPF?
- Blood tests could unlock early clues for three major lung diseases
- AI could uncover hidden lung disease in routine chest X-Rays